Tenecteplase shortage to continue

Boehringer Ingelheim has notified the TGA that its tenecteplase shortage will continue until the end of next year In August 2022, BI had told the Therapeutic Goods Administration that the thrombolytic was in shortage, due to manufacturing capacity constraints following increases in global demand. The shortage was expected to continue until the end of 2023